NEURACAP
Sector OutlookPublished · 23 pages · Free to read

Medical Devices Sector Outlook — September 2026

A sector outlook on Medical Devices covering business-model segmentation, public market valuation, precedent transactions and strategic implications, for owners, management teams and boards assessing where value sits across procedure-led franchises, diversified platforms and adjacent models.

For information only. Not an appraisal or a fairness opinion.

What moved since: Medical Devices M&A update, 14–28 September 2026

Key figures

Sector median EV/Revenue (CY2027E)
3.4x
30 of 33 rated companies
Procedure-led franchises median
3.9x
Surgical instruments & consumables
Adjacent models median
1.5x
Lower-valued segment
Premium tier median
6.7x
Vs 0.8x at discount end

Read the report

NeuraCap

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL DEVICES

Medical Devices: Premiums Sit with Faster Growth

This report shows where value sits across business models, public peers and precedent transactions.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E)

Medical Devices Coverage | September 2026 | Confidential | Not investment advice

1

1 / 23

Executive summary

Medical Devices trade across three tiers: procedure-led franchises sit at 3.9x EV/Revenue, diversified platforms at 3.4x and adjacent models at 1.5x. Faster-growing names (above 9% growth) carry 3.7x versus 2.4x below that mark, and the premium tier reaches 6.7x against 0.8x at the discount end. Because the forward multiple already prices in expected growth, the spread is associated with differing views on procedure durability and recurring revenue. Forty-four precedent transactions with disclosed terms complete the valuation picture.

Key findings

  • Procedure-led franchises price above diversified platforms and adjacent models.
  • Faster-growing names trade at a higher forward revenue multiple than slower peers.
  • The premium tier commands 6.7x versus 0.8x at the discount end of the range.
  • Precedent deals span sponsor-backed scale transactions and smaller strategic deals.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL DEVICES

    This is the cover page identifying the report as NeuraCap's Medical Devices sector outlook dated September 28, 2026.

    We're opening our Medical Devices sector outlook, built on market data as of September 28, 2026 and priced primarily on EV/Revenue for CY2027E. This framing sets up the finding we walk through next: where value concentrates across business models, public peers and precedent deals.

    Everything on this page

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL DEVICES Medical Devices: Premiums Sit with Faster Growth This report shows where value sits across business models, public peers and precedent transactions. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    This slide lists the report's five sections plus the appendix that follow.

    We've structured this report so the bottom line comes first — stop after section one and you still have the whole story. From there we move through the landscape, valuation, precedent transactions and strategic implications, so you can go as deep as you need.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Medical Devices Reward Growth That Looks Durable 02 The Landscape Procedure-Led Franchises Hold the Higher Ground 03 Valuation & Situations The Forward Premium Demands More than a Growth Forecast 04 Precedent Transactions Buyers Are Paying Across Scale, Profitability and Strategic Fit 05 Strategic Implications Strengthen the Revenue Model Behind the Forecast 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Medical Devices Split Between Diversified Platforms, Procedure-Led Franchises and Lower-Valued Adjacent Models

    This slide summarizes the report's core finding that Medical Devices splits into diversified platforms, procedure-led franchises and lower-valued adjacent models.

    We see Medical Devices splitting into three distinct value tiers rather than trading as one market. Procedure-led franchises price at 3.9x EV/Revenue, diversified platforms at 3.4x and adjacent models at 1.5x, while names above 9% growth carry 3.7x against 2.4x below that mark. The premium tier reaches 6.7x versus 0.8x at the discount end, a spread that's associated with differing views on revenue durability rather than growth forecasts alone. So the operating case for any name here turns on procedure adoption, installed base economics and reimbursement — not just the growth number.

    Everything on this page

    01 · THE BOTTOM LINE Medical Devices Split Between Diversified Platforms, Procedure-Led Franchises and Lower-Valued Adjacent Models The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (30 of 33 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (30 of 33 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Faster Growth Travels with Higher Forward Revenue Multiples Names above 9% growth sit at 3.7x, compared with 2.4x below that mark. Owners still need to connect the forecast to procedure volume, installed base growth and consumable pull-through. 2 Procedure-Led Franchises Sit Above Adjacent Models Surgical instruments and procedural consumables sit at 3.9x, diversified medtech platforms at 3.4x and adjacent models at 1.5x. The contrast puts revenue mix and account-level switching friction at the centre of the value story. 3 The Premium End Requires a Durability Case The premium end sits at 6.7x versus 0.8x at the discount end. Because the forward lens already credits expected growth, the spread is consistent with differing views on reimbursement, adoption and revenue durability. 4 Growth-Only Names Sit Near the Top of the Range Among four names clearing both 6% growth and 24% margin bars, the middle sits at 5.9x; five growth-only names sit at 6.6x. Among four names below both bars, the middle sits at 1.8x. 3.4x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because practitioners price this growth set on revenue and 5 of 33 names are… 6.7x Premium end EV/Revenue vs 0.8x at the discount end top quartile (n=8) against bottom quartile (n=7) on EV/Revenue — the spread the report explains 44 Transactions with disclosed terms 107 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    This divider introduces section two on how the market maps across business segments.

    We now turn to the market map: diversified platforms anchor the set, while surgical instruments and consumables sit higher. This sets up the segment-by-segment view on the following pages.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Procedure-Led Franchises Hold the Higher Ground Diversified platforms anchor the set, while surgical instruments and consumables sit higher. 02 of 06 Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Procedure Exposure Carries the Higher Valuation Position

    This slide groups the approved companies by business segment and shows median EV/Revenue for each group.

    We've grouped the approved universe of companies by business segment and plotted the median EV/Revenue for each. Procedure exposure clearly carries the higher valuation position in this set. That tells us where the market is already paying up — and where it isn't.

    Everything on this page

    02 · MARKET MAP Procedure Exposure Carries the Higher Valuation Position 33 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 DIVERSIFIED MEDTECH PLATFORMS 21 cos median 3.4x Medtronic (MDT) Boston Scientific (BSX) Penumbra (PEN) Globus Medical (GMED) Glaukos (GKOS) Haemonetics (HAE) TransMedics Group (TMDX) Integra (IART) AxoGen (AXGN) Alphatec Holdings (ATEC) PROCEPT (PRCT) Cerus (CERS) Delcath Systems (DCTH) Avita Medical (RCEL) Senseonics (SENS) InMode (INMD) Profound Medical (PROF) Pulmonx (LUNG) +3 more Scale and product breadth make this group the anchor for the public peer set. SURGICAL INSTRUMENTS AND PROCEDURAL CONSUMABLES 9 cos median 3.9x Intuitive Surgical (ISRG) Becton, (BDX) ResMed (RMD) West (WST) Stevanato Group (STVN) Pulse Biosciences (PLSE) Embecta (EMBC) Azenta (AZTA) Nyxoah S.A. (NYXH) Procedure exposure and recurring consumable potential place this group toward the higher end. ADJACENT MODELS 3 cos median 1.5x Alpha Tau Medical (DRTS) Cognyte Software (CGNT) Anika Therapeutics (ANIK) These businesses broaden the map but sit outside the main medtech operating pattern.

  6. 06
    02 · LANDSCAPE

    Surgical Instruments and Consumables Sit Above the Broader Platform Set

    This slide compares the surgical instruments and consumables segment median against the broader platform set.

    Looking at the segment view, surgical instruments and consumables sit above the broader diversified platform set on EV/Revenue. That gap points to account-level switching costs and consumable pull-through as differentiators. For owners in adjacent segments, closing that gap starts with strengthening recurring revenue, not simply growing faster.

    Everything on this page

    02 · LANDSCAPE Surgical Instruments and Consumables Sit Above the Broader Platform Set Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Diversified medtech platforms 21 64% 3.4x Medtronic plc (MDT) · Boston Scientific Corporation (BSX) · +19 more Scale anchors the set. Among 21 names, 20 have a forward estimate and the middle sits at 3.4x. Product breadth can support resilience, but owners still need clear franchise-level growth and capital allocation discipline. Surgical instruments and procedural consumables 9 27% 3.9x Intuitive Surgical, Inc. (ISRG) · Becton, Dickinson and Company (BDX) · +7 more Procedure exposure carries a premium. Among 9 names, 8 have a forward estimate and the middle sits at 3.9x. Procedure volume, consumable attach and physician relationships are central to the commercial case. Adjacent models 3 9% 1.5x Alpha Tau Medical Ltd (DRTS) · Cognyte Software Ltd. (CGNT) · +1 more Adjacency sits at a discount. Among 3 names, 2 have a forward estimate and the middle sits at 1.5x. The valuation gap makes business-model fit and buyer relevance important questions.

  7. 07
    SECTION 03

    03

    This divider introduces section three on public market valuation and situation analysis.

    Section three asks what the forward premium demands beyond a growth forecast. Because expected growth is already priced in, durability and revenue quality do more of the work from here.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Forward Premium Demands More than a Growth Forecast Expected growth is already reflected, increasing the importance of durability and revenue quality. 03 of 06 Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    The Valuation Range Widens When Growth Durability Comes into Focus

    This slide ranks all 30 rated companies by EV/Revenue and shows the sector median of 3.4x.

    We've sorted all 30 rated companies by EV/Revenue, and the sector median sits at 3.4x. We use EV/Revenue rather than EV/EBITDA here because five of the 33 names are loss-making on forward EBITDA, so revenue is the basis the market actually prices on. The range across this set is wide, and that spread is where the story about growth durability lives.

    Everything on this page

    03 · PUBLIC MARKET VALUATION The Valuation Range Widens When Growth Durability Comes into Focus EV / Revenue (CY2027E) · all 30 rated companies, sorted descending · sector median 3.4x · EV/Revenue is the lens because practitioners price this growth set on revenue and 5 of 33 names are loss-making on forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (30 of 33 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (30 of 33 companies), so this report follows it. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 6.7x CORE · median 3.4x DISCOUNT · median 0.8x Sector median 3.4x WHAT SEPARATES THE TWO ENDS The forward lens raises expectations. The premium end sits at 6.7x, while the discount end sits at 0.8x. Forecast growth is already reflected, so the remaining gap is consistent with different views on durability. Revenue quality still matters. Installed base economics, recurring pull-through and reimbursement support can make a growth forecast more credible through the hospital capital budget cycle. Durability remains the question. Management teams need an operating case that links account penetration, utilisation and pricing to sustained revenue performance.

  9. 09
    03 · VALUATION DRIVERS

    Profitability Separates the Two Ends: Names Above the 24% Margin Line Carry 3.9x Against 2.0x Below It

    This slide splits rated companies into growth and margin cohorts and compares their median EV/Revenue.

    When we split the rated set at its own margin median, names above the 24% EBITDA-margin line carry 3.9x versus 2.0x below it. This is an association we observe in the data, not a proven cause, but it lines up profitability with valuation more tightly than growth alone. For owners, that puts margin durability squarely on the agenda alongside topline growth.

    Everything on this page

    03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 24% Margin Line Carry 3.9x Against 2.0x Below It Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=15; slower n=14; higher-margin n=9; lower-margin n=9). Driver readings are NeuraCap views on the supplied data — association, not causation. Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 9% · EBITDA-margin split at 24% The Growth Split Is Visible in Forward Valuation The median is 3.7x for 15 names above 9% growth, compared with 2.4x for 14 names below that mark. Procedure Adoption Gives Growth Its Commercial Context Procedure volume, utilisation and consumable pull-through show whether growth is broadening within the installed base or relying on continued capital placement. Profitability Remains a Qualifier Rather than a Clean Divider The operating question is whether gross margin structure, sales productivity and manufacturing scale can support growth as the franchise matures.

  10. 10
    03 · SITUATION MAP

    Valuation and Growth Point to Different Operating Priorities

    This slide maps companies by EV/Revenue against the 3.4x sector median and revenue growth against the 9% covered median.

    We're cutting the rated set on the 3.4x sector median and the 9% growth median to see which companies sit in which situation. These are observations about where each name sits today, not recommendations. The map is a starting point for asking why a company sits where it does — and what would move it.

    Everything on this page

    03 · SITUATION MAP Valuation and Growth Point to Different Operating Priorities Cut on EV / Revenue vs the sector median (3.4x) (rows) and revenue growth vs the covered median (9%) (columns) · 1 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Higher Multiple, Higher Growth Above-median multiple · above-median revenue growth 10 names Intuitive Surgical, Inc. (ISRG) · Penumbra, Inc. (PEN) · Glaukos Corporation (GKOS) · +7 more Ten names combine above-middle growth with an above-middle forward multiple. The operating priority is to sustain adoption, capacity and recurring revenue without weakening unit economics. Higher Multiple, Lower Growth Above-median multiple · below-median revenue growth 6 names Medtronic plc (MDT) · Boston Scientific Corporation (BSX) · Becton, Dickinson and Company (BDX) · +3 more Six names retain an above-middle multiple despite below-middle growth. The priority is to protect revenue quality while finding credible sources of renewed procedure or account growth. Lower Multiple, Higher Growth Below-median multiple · above-median revenue growth 5 names Alphatec Holdings, Inc. (ATEC) · PROCEPT BioRobotics Corporation (PRCT) · Cognyte Software Ltd. (CGNT) · +2 more Five names show above-middle growth but remain below the middle of the valuation range. The value case needs clearer evidence on reimbursement, revenue mix, retention or the cost required to support growth. Lower Multiple, Lower Growth Below-median multiple · below-median revenue growth 8 names Globus Medical, Inc. (GMED) · Integra LifeSciences Holdings Corporation (IART) · Embecta Corp. (EMBC) · +5 more Eight names sit below the middle on both measures, with one name unmapped. The agenda centres on portfolio focus, cost structure and where capital can earn a stronger operating return.

  11. 11
    03 · GROWTH VS PROFITABILITY

    Growth Clears the Valuation Bar More Often than Margin Alone

    This slide plots companies with both growth and margin estimates against the 6% growth and 24% margin medians.

    Among the companies with both estimates, we cut at 6% growth and 24% margin to see which quadrant clears the valuation bar. Growth clears that bar more often than margin alone in this set. That's a useful signal for where the market is currently rewarding effort — though it doesn't tell us which lever pays off for any single company.

    Everything on this page

    03 · GROWTH VS PROFITABILITY Growth Clears the Valuation Bar More Often than Margin Alone Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2026E, y-axis) · 18 companies with both estimates · cuts at the covered medians (6% growth, 24% margin) · median EV/Revenue per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/Revenue (balanced n=4; margin-only n=5; growth-only n=5; neither n=4). Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 5% 10% 15% 20% 0% 10% 20% 30% 40% MARGIN ONLY median 3.4x BALANCED median 5.9x NEITHER median 1.8x GROWTH ONLY median 6.6x BDX IART RMD BSX MDT INGN ANIK AZTA GMED WST HAE STVN ISRG PEN ATEC TMDX AXGN GKOS x: revenue growth (CY2027E) · y: EBITDA margin (CY2026E) HOW TO READ THIS The chart separates names at 6% growth and 24% margin. Among four names above both bars, the middle sits at 5.9x. Among five growth-only names, the middle sits at 6.6x; among four names below both bars, it sits at 1.8x. The small groups make this a directional view rather than a broad rule. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 3 of 18 names clear it (ISRG, RMD, GMED).

  12. 12
    03 · THE AGENDA

    Mix, Pricing and Retention Are the Levers Open to Owners at Both Ends of the Range

    This slide lays out the operating questions owners and acquirers should resolve at both ends of the valuation range.

    We frame mix, pricing and retention as the levers open to owners regardless of where they sit on the valuation range today. These are observations drawn from the cohort data, not recommendations to act on any specific security. The question for any owner is which of these levers moves the needle fastest for their business.

    Everything on this page

    03 · THE AGENDA Mix, Pricing and Retention Are the Levers Open to Owners at Both Ends of the Range NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Deepen the Recurring Revenue Model Increase utilisation, consumable attach and account penetration around the installed base rather than relying mainly on new capital placements. What changes the answer: The answer changes when pull-through improves without a matching increase in selling cost. Concentrate Resources Behind the Franchise Direct capital and commercial capacity toward products with established reimbursement, physician adoption and a credible path into adjacent indications. What changes the answer: The answer changes when a franchise shows repeatable procedure growth across accounts and channels. Rework the Cost Structure for Scale Align manufacturing, channel cost and sales coverage with the revenue mix the business can support through the next phase of growth. What changes the answer: The answer changes when incremental revenue begins to convert into durable operating contribution. Test Build Versus Buy Compare internal development with targeted product or channel additions that can deepen the procedural bag or accelerate account access. What changes the answer: The answer changes when acquisition economics offer a clearer return than internal development and commercial build-out.

  13. 13
    SECTION 04

    04

    This divider introduces section four on precedent transactions.

    Section four turns to the transaction record itself. Buyers here have paid across scale, profitability and strategic fit, spanning both sponsor-backed scale deals and smaller strategic combinations.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Buyers Are Paying Across Scale, Profitability and Strategic Fit The transaction record spans sponsor-backed scale deals and smaller strategic combinations. 04 of 06 Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13

  14. 14
    04 · DEAL CASE STUDIES

    Precedent Transactions Show What Buyers Agreed to Pay for Whole Companies Here

    This slide walks through three of the 44 disclosed-terms transactions as case studies.

    We highlight three of the 44 transactions with disclosed terms as case studies, with multiples on LTM financials at announcement. These deals aren't directly comparable to the CY2027E public basis, so we don't claim a spread between the two. What they do show is what buyers have actually agreed to pay for whole companies in this sector.

    Everything on this page

    04 · DEAL CASE STUDIES Precedent Transactions Show What Buyers Agreed to Pay for Whole Companies Here 3 of 44 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 122 precedent record(s) carry data-quality flags (carve out target recorded as parent; deal value unit unresolved; divestiture roles reassigned); figures are shown as recorded in the filing. 63 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Oct-2025 $18.3B Blackstone Inc.; TPG Capital Blackstone Inc.; TPG Capital acquires Hologic, Inc EV / LTM revenue 4.3x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED Blackstone Inc.; TPG Capital moved for Hologic, Inc in Oct-2025; the record shows it as completed. HOW THE TARGET WAS VALUED The filing records $18.3B of enterprise value, struck at 4.3x LTM revenue, the benchmark buyers in this segment start from. Aug-2026 $5.7B KKR KKR acquires Integer Holdings Corporation EV / LTM revenue 3.2x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED KKR moved for Integer Holdings Corporation in Aug-2026; the record shows it as announced. HOW THE TARGET WAS VALUED The filing records $5.7B of enterprise value, struck at 3.2x LTM revenue, the benchmark buyers in this segment start from. Jan-2024 $2.7B Boston Scientific Corporation Boston Scientific Corporation acquires Axonics, Inc. EV / LTM revenue 9.4x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED Boston Scientific Corporation moved for Axonics, Inc. in Jan-2024; the record shows it as announced. HOW THE TARGET WAS VALUED The filing records $2.7B of enterprise value, struck at 9.4x LTM revenue, the benchmark buyers in this segment start from.

  15. 15
    SECTION 05

    05

    This divider introduces section five on strengthening the revenue model behind the forecast.

    Section five turns from what the market pays to what supports the forecast. Procedure growth, installed base economics and recurring pull-through are the pieces that shape the value case from here.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS Strengthen the Revenue Model Behind the Forecast Procedure growth, installed base economics and recurring pull-through shape the value case. 05 of 06 Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15

  16. 16
    05 · STRATEGIC IMPLICATIONS

    The Value Case Starts with Revenue Quality and Ends with Operating Proof

    This slide sets out the strategic questions this analysis raises for the next twelve months.

    We close the analysis with the questions this data puts on the table: for owners, management and boards. This is directional judgment grounded in the analysis shown earlier, not a recommendation. The value case starts with revenue quality and ends with operating proof.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS The Value Case Starts with Revenue Quality and Ends with Operating Proof NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Make Growth Durable at the Account Level Focus on utilisation, consumable pull-through, pricing and retention within the installed base. These operating measures show whether growth can persist beyond new placements. FOR MANAGEMENT TEAMS Match Commercial Spend to Procedure Economics Prioritise territories, indications and channels where procedure volume can support sales productivity and account depth. FOR BOARDS Allocate Capital Around Franchise Evidence Compare portfolio investment, cost restructuring and targeted acquisitions against the durability of reimbursement, adoption and recurring revenue.

  17. 17
    SECTION 06

    06

    06.

    Section 06 of 06 — The Full Universe, Methodology and Sources. Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. Use this divider to reset the room before the section's pages; the progress dots show where the argument stands. 17

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17

  18. 18
    06 · PUBLIC COMPARABLES (1 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This appendix page lists the rated public comparables on EV/Revenue, grouped by valuation tier.

    Here we list the rated comparables on EV/Revenue, shaded against the 3.4x sector median. Thirty companies are rated; three sit outside the rated set for lacking an eligible multiple. This is the underlying detail behind every multiple quoted earlier in the report.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (3.4x); amber marks below · 30 rated companies; 3 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 30 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥4.0x · median 6.7x · 8 companies Glaukos Corporation GKOS Diversified medtech platforms $9.1B 10.8x 22% 11% 40 Intuitive Surgical, Inc. ISRG Surgical instruments and procedural consumables $143B 10.7x 13% 45% 57 West Pharmaceutical Services, Inc. WST Surgical instruments and procedural consumables $26.4B 7.4x 6% 28% 35 Penumbra, Inc. PEN Diversified medtech platforms $12.2B 6.8x 13% 16% 29 AxoGen, Inc. AXGN Diversified medtech platforms $2.2B 6.6x 20% 10% 32 ResMed Inc. RMD Surgical instruments and procedural consumables $31.4B 5.3x 4% 39% 44 Stevanato Group S.p.A. STVN Surgical instruments and procedural consumables $6.9B 4.3x 9% 27% 38 Profound Medical Corp. PROF Diversified medtech platforms $172M 4.1x 68% n/a n/a CORE — 1.7x–4.0x · median 3.4x · 15 companies Haemonetics Corporation HAE Diversified medtech platforms $5.8B 3.9x 6% 30% 38 Senseonics Holdings, Inc. SENS Diversified medtech platforms $389M 3.9x 56% n/a n/a TransMedics Group, Inc. TMDX Diversified medtech platforms $3.2B 3.7x 18% 14% 36 Avita Medical Inc. RCEL Diversified medtech platforms $393M 3.6x 26% n/a n/a Delcath Systems, Inc. DCTH Diversified medtech platforms $457M 3.5x 24% n/a n/a Boston Scientific Corporation BSX Diversified medtech platforms $75.4B 3.4x 4% 31% 35 Becton, Dickinson and Company BDX Surgical instruments and procedural consumables $67.1B 3.4x 3% 30% n/a

  19. 19
    06 · PUBLIC COMPARABLES (2 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This appendix page continues the rated public comparables list on EV/Revenue by valuation tier.

    This page continues the comparables table, again shaded against the 3.4x sector median. Together with the prior page, it covers all 30 rated companies. Use it to trace any multiple referenced earlier back to the specific company.

    Everything on this page

    06 · PUBLIC COMPARABLES (2 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (3.4x); amber marks below · 30 rated companies; 3 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 30 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 CORE — CONTINUED — 1.7x–4.0x · median 3.4x · 15 companies Medtronic plc MDT Diversified medtech platforms $135B 3.4x 4% 27% 32 Globus Medical, Inc. GMED Diversified medtech platforms $9.6B 2.8x 6% 34% 41 Alphatec Holdings, Inc. ATEC Diversified medtech platforms $2.0B 2.0x 15% 16% 33 Azenta, Inc. AZTA Surgical instruments and procedural consumables $1.3B 1.9x 5% 14% n/a Cerus Corporation CERS Diversified medtech platforms $509M 1.8x 9% n/a n/a Anika Therapeutics, Inc. ANIK Specialty therapeutic device franchises $235M 1.8x 5% 16% 22 Integra LifeSciences Holdings Corporation IART Diversified medtech platforms $3.0B 1.8x 3% 20% 25 PROCEPT BioRobotics Corporation PRCT Diversified medtech platforms $814M 1.7x 21% n/a n/a DISCOUNT — <1.7x · median 0.8x · 7 companies Embecta Corp. EMBC Surgical instruments and procedural consumables $1.5B 1.4x 5% n/a n/a Cognyte Software Ltd. CGNT Adjacent: enterprise security analytics software $574M 1.2x 10% n/a n/a InMode Ltd. INMD Diversified medtech platforms $368M 1.0x 2% n/a n/a Sensus Healthcare, Inc. SRTS Diversified medtech platforms $28M 0.8x 45% n/a 52 Nyxoah S.A. NYXH Surgical instruments and procedural consumables $55M 0.7x n/a n/a n/a Pulmonx Corporation LUNG Diversified medtech platforms $60M 0.6x 19% n/a n/a Inogen, Inc. INGN Diversified medtech platforms $56M 0.2x 5% 1% 7

  20. 20
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This appendix page lists the precedent transactions with disclosed terms, newest first.

    This page opens the full list of 44 transactions with disclosed terms, ordered newest first, with multiples on LTM financials at announcement. A number of the recorded transactions carry data-quality flags, and those are shown as recorded rather than adjusted. This is the transaction-level detail behind the case studies discussed earlier.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 44 transactions with disclosed terms in this tier (107 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 122 precedent record(s) carry data-quality flags (carve out target recorded as parent; deal value unit unresolved; divestiture roles reassigned); figures are shown as recorded in the filing. 63 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 44 transactions shown; the rest are in the companion workbook. Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Aug-2026 KKR → Integer Holdings Corporation $5.7B 3.2x n/a KKR paid $5.7B at 3.2x LTM revenue. Jul-2026 MiMedx Group, Inc. → Sanara MedTech Inc. $350M 3.2x 18.5x MiMedx Group, Inc. paid $350M at 3.2x LTM revenue. Apr-2026 Undisclosed buyer → CONMED Corporation $2.0B 1.5x 7.9x Undisclosed buyer paid $2.0B at 1.5x LTM revenue. Dec-2025 n/a → FONAR Corporation $103M 0.3x 2.0x n/a paid $103M at 0.3x LTM revenue. Dec-2025 1567208 B.C. Ltd. → Quipt Home Medical Corp. $264M 1.0x 4.5x 1567208 B.C. Ltd. paid $264M at 1.0x LTM revenue. Oct-2025 Blackstone Inc.; TPG Capital → Hologic, Inc $18.3B 4.3x n/a Blackstone Inc.; TPG Capital paid $18.3B at 4.3x LTM revenue. May-2025 Gregg G Williams 2006 Irrevocable Trust → Vivani Medical, Inc. $63M n/a n/a Gregg G Williams 2006 Irrevocable Trust paid $63M. Feb-2025 Globus Medical, Inc. → Nevro Corp. $374M 0.9x n/a Globus Medical, Inc. paid $374M at 0.9x LTM revenue. Nov-2024 Standex International Corporation → Arctic Solutions, Inc. $6M n/a n/a Standex International Corporation paid $6M.

  21. 21
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This appendix page continues the list of precedent transactions with disclosed terms.

    This page completes the precedent transaction list, covering the remaining disclosed-terms deals. Together with the prior page, it gives the full record behind the transaction discussion earlier in the report. The complete set, including transactions without disclosed values, sits in the companion workbook.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 44 transactions with disclosed terms in this tier (107 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 122 precedent record(s) carry data-quality flags (carve out target recorded as parent; deal value unit unresolved; divestiture roles reassigned); figures are shown as recorded in the filing. 63 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 44 transactions shown; the rest are in the companion workbook. Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Aug-2024 UFP Technologies, Inc. → AQF Medical n/a n/a 12.3x Jan-2024 Boston Scientific Corporation → Axonics, Inc. $2.7B 9.4x n/a Value shown as recorded in the filing; deal value unit unresolved. Oct-2023 Patient Square Capital, LP → Eargo, Inc. n/a 0.7x 8.8x Aug-2023 Bruker Corporation → PhenomeX Inc. n/a 1.0x n/a Dec-2021 Rayner Surgical Inc. → OMEROS CORPORATION $791M 8.7x n/a Value shown as recorded in the filing; deal value unit unresolved. Sep-2021 Baxter International Inc. → Hill-Rom Holdings, Inc. n/a n/a 18.9x Sep-2021 ZOLL Medical Corporation → Itamar Medical Ltd. n/a 9.9x n/a Aug-2021 Medtronic PLC → Intersect ENT, Inc. n/a 10.5x n/a Value shown as recorded in the filing; deal value unit unresolved. Dec-2020 Vesper Healthcare Acquisition Corp. → HydraFacial $1.1B n/a n/a

  22. 22
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This slide explains the report's sources, valuation basis and data-quality treatment.

    This page sets out how we built the report: the valuation basis, what was excluded and why. Every figure in the body traces back to its underlying source, whether a filing, a consensus estimate or a market price. That traceability is what lets you verify any number in this deck rather than take it on faith.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Medical Devices Coverage | September 2026 | Confidential | Not investment advice 22 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (30 of 33 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (30 of 33 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Medical Devices and it clears the coverage gate with 30 of 33 companies (91%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (17 of 33 names with a meaningful EBITDA). DATA QUALITY & EXCLUSIONS 81 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 1379 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (1378) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  23. 23

    In This Sample, the Premium Sits with Faster Growth and a More Durable Revenue Story.

    This is the closing slide restating that the premium sits with faster growth and a more durable revenue story.

    We end where we started: in this sample, the premium sits with faster growth and a more durable revenue story. The companion tables carry the full universe and source index for any figure you want to trace further.

    Everything on this page

    In This Sample, the Premium Sits with Faster Growth and a More Durable Revenue Story. NeuraCap AI — Medical Devices Coverage September 2026 · Prepared by NeuraCap AI · Confidential Medical Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 23

Sources and methodology

This report covers Medical Devices (Health Care › Health Care Equipment and Services › Medical Devices) with market data and consensus estimates as of September 28, 2026. The company universe is the 33 listed companies whose core business is Medical Devices according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Anika Therapeutics, Inc. (ANIK), Alphatec Holdings, Inc. (ATEC), AxoGen, Inc. (AXGN), Azenta, Inc. (AZTA), Becton, Dickinson and Company (BDX), Boston Scientific Corporation (BSX), Cerus Corporation (CERS), Cognyte Software Ltd. (CGNT), Delcath Systems, Inc. (DCTH), Alpha Tau Medical Ltd (DRTS), Embecta Corp. (EMBC), Glaukos Corporation (GKOS), Globus Medical, Inc. (GMED), Haemonetics Corporation (HAE), Integra LifeSciences Holdings Corporation (IART), Inogen, Inc. (INGN), InMode Ltd. (INMD), Intuitive Surgical, Inc. (ISRG), Pulmonx Corporation (LUNG), Medtronic plc (MDT), Nyxoah S.A. (NYXH), Penumbra, Inc. (PEN), Pulse Biosciences, Inc. (PLSE), PROCEPT BioRobotics Corporation (PRCT), Profound Medical Corp. (PROF), Avita Medical Inc. (RCEL), ResMed Inc. (RMD), RxSight, Inc. (RXST), Senseonics Holdings, Inc. (SENS), Sensus Healthcare, Inc. (SRTS), Stevanato Group S.p.A. (STVN), TransMedics Group, Inc. (TMDX), West Pharmaceutical Services, Inc. (WST). The market map groups them by business vertical — Diversified medtech platforms: 21 companies (MDT, BSX, PEN, GMED, GKOS, HAE, TMDX, IART, AXGN, ATEC, PRCT, CERS, DCTH, RCEL, SENS, INMD, PROF, LUNG, INGN, SRTS, RXST); Surgical instruments and procedural consumables: 9 companies (ISRG, BDX, RMD, WST, STVN, PLSE, EMBC, AZTA, NYXH); Adjacent models: 3 companies (DRTS, CGNT, ANIK). 30 of the 33 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statis

Scope and company universe

This report covers Medical Devices (Health Care › Health Care Equipment and Services › Medical Devices) with market data and consensus estimates as of September 28, 2026. The company universe is the 33 listed companies whose core business is Medical Devices according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Anika Therapeutics, Inc. (ANIK), Alphatec Holdings, Inc. (ATEC), AxoGen, Inc. (AXGN), Azenta, Inc. (AZTA), Becton, Dickinson and Company (BDX), Boston Scientific Corporation (BSX), Cerus Corporation (CERS), Cognyte Software Ltd. (CGNT), Delcath Systems, Inc. (DCTH), Alpha Tau Medical Ltd (DRTS), Embecta Corp. (EMBC), Glaukos Corporation (GKOS), Globus Medical, Inc. (GMED), Haemonetics Corporation (HAE), Integra LifeSciences Holdings Corporation (IART), Inogen, Inc. (INGN), InMode Ltd. (INMD), Intuitive Surgical, Inc. (ISRG), Pulmonx Corporation (LUNG), Medtronic plc (MDT), Nyxoah S.A. (NYXH), Penumbra, Inc. (PEN), Pulse Biosciences, Inc. (PLSE), PROCEPT BioRobotics Corporation (PRCT), Profound Medical Corp. (PROF), Avita Medical Inc. (RCEL), ResMed Inc. (RMD), RxSight, Inc. (RXST), Senseonics Holdings, Inc. (SENS), Sensus Healthcare, Inc. (SRTS), Stevanato Group S.p.A. (STVN), TransMedics Group, Inc. (TMDX), West Pharmaceutical Services, Inc. (WST). The market map groups them by business vertical — Diversified medtech platforms: 21 companies (MDT, BSX, PEN, GMED, GKOS, HAE, TMDX, IART, AXGN, ATEC, PRCT, CERS, DCTH, RCEL, SENS, INMD, PROF, LUNG, INGN, SRTS, RXST); Surgical instruments and procedural consumables: 9 companies (ISRG, BDX, RMD, WST, STVN, PLSE, EMBC, AZTA, NYXH); Adjacent models: 3 companies (DRTS, CGNT, ANIK). 30 of the 33 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

81 records failed a validation gate and never feed a statistic in this report (79 excluded from aggregate; 2 quarantined). Each exclusion, with its reason: ANIK — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ANIK — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ATEC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AXGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AZTA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CERS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CERS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CERS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CERS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CGNT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DCTH — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DCTH — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DRTS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DRTS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DRTS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DRTS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · GKOS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · GKOS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · GKOS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · IART — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · INGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · INGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · INGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · INGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LUNG — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.

Primary valuation basis and how it was chosen

Primary valuation basis: EV / Revenue on CY2027E consensus (30 of 33 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (30 of 33 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Medical Devices and it clears the coverage gate with 30 of 33 companies (91%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (17 of 33 names with a meaningful EBITDA). The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 17 of 33 companies; EV / rEVenue: 32 of 33 companies; P/E: 20 of 33 companies. 5 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 13 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥4.0x, Core 1.7x–4.0x, Discount <1.7x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 3.4x = median(ev_revenue CY2027E) (30 rated companies) · 6.7x = median(ev_revenue CY2027E) within Premium tier (n=8) · 3.4x = median(ev_revenue CY2027E) within Core tier (n=15) · 0.8x = median(ev_revenue CY2027E) within Discount tier (n=7) · 3.7x = median(ev_revenue CY2027E) | growth ≥ 9% (n=15) · 2.4x = median(ev_revenue CY2027E) | growth < 9% (n=14) · 3.9x = median(ev_revenue CY2027E) | EBITDA margin ≥ 24% (n=9) · 2.0x = median(ev_revenue CY2027E) | EBITDA margin < 24% (n=9) · 32% = median Rule of 40 score (revenue growth + EBITDA margin) (n=18) · 5.9x = median(ev_revenue CY2027E) within balanced quadrant (n=4) · 3.4x = median(ev_revenue CY2027E) within marginOnly quadrant (n=5) · 6.6x = median(ev_revenue CY2027E) within growthOnly quadrant (n=5) · 1.8x = median(ev_revenue CY2027E) within neither quadrant (n=4)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Medical Devices recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 107 transactions were recorded for this industry; 44 are shown. 63 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 59 × deal value unit unresolved; 44 × no evidence record; 10 × duplicate precedent id; 8 × divestiture roles reassigned; 1 × carve out target recorded as parent. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 1383 source documents stand behind this report; by publisher domain: sec.gov (1378), home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Medical Devices?

Company valuation reports run the same method against a single business — public or private.